Vernakalant hydrochloride for the treatment of atrial fibrillation

Expert Opinion on Investigational Drugs

Volumn 18, Issue 12, 2009, Pages 1929-1937

  Kozlowski, Dariusz ^a   Budrejko, Szymon ^a   Lip, Gregory Y H ^b   Mikhailidis, Dimitri P ^c   Rysz, Jacek ^d   Raczak, Grzegorz ^a   Banach, MacIej ^d  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Atrial fibrillation; RSD1235; Vernakalant; Vernakalant hydrochloride

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ANTIARRHYTHMIC AGENT; AVE 1231; CLOFILIUM; DOFETILIDE; DPO 1; FLECAINIDE; GAP JUNCTION PROTEIN; ION CHANNEL; NEW DRUG; NIP 141; NIP 142; PLACEBO; PROPAFENONE; QUINIDINE; TERTIAPIN; UNCLASSIFIED DRUG; VERNAKALANT;

ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOGENIC SHOCK; CARDIOSELECTIVITY; CLINICAL TRIAL; CONTROL STRATEGY; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG SCREENING; DYSGEUSIA; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PROARRHYTHMIA; HEART RHYTHM; HEART VENTRICLE; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOTENSION; INTRAVENOUS ADMINISTRATION; NAUSEA; ORAL PARESTHESIA; PARESTHESIA; PHYSIOLOGY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REPOLARIZATION; REVIEW; SIDE EFFECT; SINUS RHYTHM; SNEEZING; SODIUM CURRENT; SYSTEMATIC REVIEW; TASTE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANIMALS; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HUMANS; INJECTIONS, INTRAVENOUS; PYRROLIDINES;

EID: 72249094388     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903386246     Document Type: Review

References (56)

1. Feinberg W, Cornell ES, Nightingale SD, et al. Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Stroke 1997;28:1101-1106
2. Banach M, Kourliouros A, Reinhart KM, et al. Postoperative atrial fibrillation-what do we really know? Curr Vasc Pharmacol 2010. In press
3. Friberg J, Buch P, Scharling H, et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666-672
4. Wattigney W, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-716
5. Stewart S, MacIntyre K, MacLeod MM, et al. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. Eur Heart J 2001;22:693-701
6. Benjamin E, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-844
7. Go A, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375
8. Mariscalco G, Klersy C, Zanobini M, et al. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 2008;118:1612-1618
9. Feinberg W, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-473
10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57
11. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359-64
12. Wyse D, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833 (Pubitemid 35417773)
13. Van Gelder I, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840
14. Hohnloser S, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-1794
15. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745
16. Mariscalco G, Sala A, Banach M, Cattaneo P. Dofetilide for the prevention of postoperative atrial fibrillation after coronary surgery: is it a useful routine prophylaxis? Am J Cardiol 2008;102:506
17. Tamargo J, Caballero R, Delpón E. Pharmacological approaches in the treatment of atrial fibrillation. Curr Med Chem 2004;11:13-28
18. Li G, Feng J, Yue L, et al. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res 1996;78:689-696 (Pubitemid 26106881)
19. Ehrlich JR, Nattel S. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope? Curr Opin Cardiol 2009;24:50-55
20. Conway E, Musco S, Kowey PR. New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Am J Cardiol 2008;102:12H-19H
21. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005;16:1227-1238
22. Cheng JWM. Vernakalant in the management of atrial fibrillation. Ann Pharmacother 2008;42:533-542
23. Ehrlich JR, Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs 2009;69:757-774
24. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 2007;16:519-532
25. Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res 2009;2:4
26. Eldstrom J, Wang Z, Xu H, et al. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol Pharmacol 2007;72:1522-34
27. Orth PM, Hesketh JC, Mak CK, et al. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 2006;70:486-496
28. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-1525
29. Dorian P, Pinter A, Mangat I, et al. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007;50:35-40
30. Banach M, Mariscalco G, Ugurlucan M, et al. The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation-still underestimated opponent. Europace 2008;10:1266-1270
31. Cardiome announces USAN name and patent grant. Available from: http://www. cardiome.com
32. Nortran drug effective in atrial arrhythmia model Available from: http://www.cardiome.com
33. Nortran initiates phase 1 study for RSD1235 Available from: http://www. cardiome.com
34. Cardiome pharma completes phase 1 safety study Available from: http://www. cardiome.com
35. Cardiome drug effective for heart patients Available from: http://www.cardiome.com
36. Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-2361
37. Cardiome's pivotal AF study achieves primary endpoint. Available from: http://www.cardiome.com
38. Cardiome and Astellas announce positive results from ACT 2 trial Available from: http://www.cardiome.com
39. Cardiome and Astellas announce positive results from second phase 3 trial Available from: http://www.cardiome.com
40. Dell'Orfano JT, Patel H, Wolbrette DL, et al. Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am J Cardiol 1999;83:788-790
41. Danias PG, Caulfield TA, Weigner MJ, et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998;31:588-592
42. Naccarelli GV, Dell'Orfano JT, Wolbrette DL, et al. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol 2000;85(10A):36D-45D
43. Capucci A, Boriani G, Rubino I, et al. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 1994;43:305-313
44. Cardiome and Astellas initiate ACT 4 study. Available from: http://www.cardiome.com
45. Nortran antiarrhythmia drug demonstrates oral bioavailability Available from: http://www.cardiome.com
46. Cardiome reports oral absorption of RSD1235 in humans Available from: http://www.cardiome.com
47. Cardiome selects oral RSD1235 formulation Available from: http://www.cardiome.com
48. Cardiome successfully completes second phase 1 trial Available from: http://www. cardiome.com
49. Cardiome reports additional phase 1 trial data for oral RSD1235 Available from: http://www.cardiome.com
50. Cardiome announces positive phase 2a results for oral RSD1235 Available from: http://www.cardiome.com
51. Cardiome announces positive phase 2b results for oral vernakalant Available from: http://www.cardiome.com
52. Banach M, Rysz J, Drozdz JA, et al. Risk factors of atrial fibrillation following coronary artery bypass grafting: a preliminary report. Circ J 2006;70:438-441
53. Banach M, Goch A, Misztal M, et al. Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg 2007;134:1569-1576
54. Banach M, Misztal M, Goch A, et al. Predictors of atrial fibrillation in patients following isolated surgical revascularization. A metaanalysis of 9 studies with 28 786 patients. Arch Med Sci 2007;3:229-239
55. Khoo CW, Lip GY. Burden of atrial fibrillation. Curr Med Res Opin 2009;25:1261-3
56. Benussi S, Galanti A, Alfieri O. Restoring sinus rhythm in patients at a high risk for postoperative atrial fibrillation. Arch Med Sci 2008;4:108-115